Phreesia (PHR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing ...

Group 1 - The article discusses the positive growth outlook for Phreesia (PHR), highlighting the potential for new logo additions to drive business expansion [1] - The author emphasizes a fundamentals-based approach to value investing, focusing on companies with long-term durability and robust balance sheets [1] - There is a critique of the misconception that low multiple stocks are inherently cheap, advocating for a focus on long-term growth rather than immediate price concerns [1] Group 2 - The article does not contain any disclosures related to stock positions or business relationships with the companies mentioned [2] - It clarifies that past performance is not indicative of future results and that no specific investment recommendations are provided [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or oth ...

Phreesia (PHR) reported $115.94 million in revenue for the quarter ended April 2025, representing a year-over-year increase of 14.5%. EPS of -$0.07 for the same period compares to -$0.35 a year ago.The reported revenue represents a surprise of +1.09% over the Zacks Consensus Estimate of $114.69 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +46.15%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Phreesia (PHR) Q1 2026 Earnings Call May 28, 2025 08:30 AM ET Company Participants Balaji Gandhi - CFOChaim Indig - Co-Founder, CEO & DirectorAnne Samuel - Executive DirectorJailendra Singh - Managing DirectorRichard Close - Managing DirectorJohn Ransom - Managing Director, Director of Healthcare ResearchWilliam Jellison - Associate VPJeff Garro - Managing DirectorScott Schoenhaus - Managing DirectorJared Haase - Equity Research AssociateAaron Kimson - Vice President Conference Call Participants Jessica Tas ...

Financial Performance and Key Metrics - Revenue for Q1 2026 was $115.9 million, representing a 15% year-over-year increase [9] - Adjusted EBITDA was $20.8 million, an increase of 16.7% year-over-year, with an adjusted EBITDA margin of 18% [10] - Average healthcare services clients increased to 4,411, up 70 from the prior quarter and 346 from the prior year [9] - Total revenue per average healthcare services client was $26,283, up 6% year-over-year and 4% quarter-over-quarter [9] - Cash and cash equivalents at the end of the quarter were $90.9 million, compared to $84.2 million in the prior quarter [10] - Positive operating cash flow of $14.9 million, up $15.6 million year-over-year, and positive free cash flow of $7.5 million, up $13.7 million year-over-year [11] Business Line Performance - The company is focused on delivering scalable products that drive meaningful outcomes for patients and providers, with AI integration across all aspects of the organization [6] - The company is maintaining its revenue outlook for fiscal year 2026 at a range of $472 million to $482 million, with an updated adjusted EBITDA outlook of $85 million to $90 million [12] Market Data and Key Metrics - The company is reiterating its outlook on average healthcare services clients (AHSCs) to reach approximately 4,500 in fiscal year 2026 [12] Company Strategy and Industry Competition - The company emphasizes product-led growth and aims to allocate capital to drive long-term shareholder value [6] - Management highlighted the importance of delivering products that provide value, which is crucial in a competitive market [23] Management Commentary on Operating Environment and Future Outlook - Management noted that conversations with customers remain strong, and the company has been resilient amid macroeconomic volatility [15] - The company is optimistic about its ability to grow its network and expand offerings, driven by a strong balance sheet and growing free cash flow [6][11] Other Important Information - The company has a share repurchase plan for up to 2.5 million shares, aimed at being opportunistic in response to market conditions [80][82] - The Medifine acquisition is still in its early stages, but it is expected to contribute to revenue growth in the future [94][96] Q&A Session Summary Question: Insights on network solutions growth and customer conversations - Management indicated that strong product development and a capable network solutions team are driving growth, with no significant hesitancy reported from customers [15][18] Question: Provider market conversations and outlook - Management noted that conversations with providers remain focused on delivering value through products, with no significant changes in the competitive landscape [22][23] Question: ROI visibility for network solutions customers - Management explained that campaigns can be adjusted based on client needs, and the company has a strong ROI, which drives continued investment from clients [27][29] Question: Sales and marketing performance - Management highlighted that previous investments in sales and marketing are yielding returns, with expectations for consistent expense trends moving forward [34][35] Question: Capital deployment opportunities - Management stated that while the cash position is improving, the evaluation of inorganic opportunities remains consistent, focusing on the best approach to growth [39][41] Question: Impact of flu season on performance - Management clarified that while there are seasonal factors, the introduction of new products like the patient bill pay product is contributing to volume growth [50][51] Question: Labor strategy and expense trajectory - Management explained that recent headcount changes were due to consolidation rather than new hiring, and the expense trajectory is expected to remain stable [53][54] Question: Proposed legislation on drug advertisements - Management indicated that while legislation is always a topic, the focus remains on the value proposition of their platform, which is differentiated [56][58] Question: Network solutions seasonality - Management noted that fluctuations in revenue are more related to program pacing rather than strict seasonality [60][61] Question: Subscription revenue growth - Management confirmed that the growth in revenue per provider client reflects successful product introductions and expansion within existing clients [65][67] Question: AI's impact on competitive landscape - Management observed that AI is enhancing their product offerings and driving value for clients, with a shift towards being a trusted partner in the market [74][76] Question: Share repurchase plan motivation - Management described the share repurchase plan as a means to be opportunistic in response to market volatility, without indicating a change in capital allocation strategy [80][82] Question: Cash conversion rates and payment processing revenue - Management indicated that cash conversion rates are expected to resemble Q1 performance for the rest of the year, with payment processing revenue following historical trends [86][88] Question: Monetization of Medifine offering - Management stated that Medifine is in the early stages of monetization but is expected to grow as the network expands [94][96]

Investor Presentation FIRST QUARTER | FISCAL YEAR 2026 Forward Looking Statements This presentation includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operational performance and may contain projections of our future results o ...

Financial Performance - Total revenue for the first quarter was $115.9 million, representing a 15% year-over-year increase[8] - Adjusted EBITDA for the quarter was $20.8 million, compared to $4.1 million in the same period last year[8] - Net loss for the quarter was $3.9 million, significantly improved from a net loss of $19.7 million in the prior year[8] - Total revenues for the three months ended April 30, 2025, were $115,936,000, a 14.5% increase from $101,217,000 in the same period of 2024[20] - Adjusted EBITDA for the three months ended April 30, 2025, was $20,816,000, compared to $4,093,000 in the same period of 2024, indicating a substantial increase[32] - Net loss for the three months ended April 30, 2025, was $3,914,000, significantly improved from a net loss of $19,722,000 in the same period of 2024[22] - The company reported a comprehensive loss of $3,479,000 for the three months ended April 30, 2025, compared to a comprehensive loss of $19,721,000 in the same period of 2024[22] Client Metrics - Average number of healthcare services clients (AHSCs) was 4,411, up 9% year-over-year[8] - Average number of healthcare services clients (AHSCs) rose to 4,411 in Q1 2025 from 4,065 in Q1 2024, reflecting a growth of 8.5%[39] - The company expects to reach approximately 4,500 AHSCs in fiscal 2026, with total revenue per AHSC projected to increase from fiscal 2025[5] Revenue per Client - Total revenue per AHSC was $26,283, an increase of 6% year-over-year[8] - Total revenue per AHSC increased to $26,283 in Q1 2025 from $24,900 in Q1 2024, marking a growth of 5.5%[39] Cash Position - Cash and cash equivalents as of April 30, 2025, were $90.9 million, up $6.7 million from January 31, 2025[8] - Cash and cash equivalents at the end of the period were $90,871,000, up from $79,527,000 at the end of the same period in 2024[24] - Net cash provided by operating activities was $14,850,000 for the three months ended April 30, 2025, compared to a cash outflow of $721,000 in the same period of 2024[24] - The company had no borrowings outstanding under its credit facility as of April 30, 2025, providing additional capital flexibility for growth opportunities[6] Revenue Outlook - The company maintains its revenue outlook for fiscal 2026, expecting revenue between $472 million and $482 million[4] - Adjusted EBITDA outlook for fiscal 2026 has been updated to a range of $85 million to $90 million, up from a previous range of $78 million to $88 million[5] Payment Metrics - Patient payment volume for Q1 2025 reached $1,314 million, up from $1,166 million in Q1 2024, representing an increase of approximately 12.7%[42] - Payment facilitator volume percentage increased to 82% in Q1 2025 from 81% in Q1 2024, indicating a slight growth in the proportion of transactions processed as a payment facilitator[42] - The company views patient payment volume as a key indicator of the health of its healthcare services clients' businesses and the shift of healthcare costs to patients[42] - Payment facilitator volume is a major driver of the company's payment processing revenue, with potential for slight decline in percentage as enterprise customer penetration increases[42] Expense Management - Total expenses decreased to $119,223,000 in Q1 2025 from $120,637,000 in Q1 2024, a reduction of 1.2%[20]

The upcoming report from Phreesia (PHR) is expected to reveal quarterly loss of $0.13 per share, indicating an increase of 62.9% compared to the year-ago period. Analysts forecast revenues of $114.69 million, representing an increase of 13.3% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announces its earnings, it is e ...

Group 1 - The stock of Phreesia (PHR) closed at $24.84, showing a 2.6% increase over the past four weeks, with a mean price target of $31.80 indicating a potential upside of 28% [1] - Analysts have set 15 short-term price targets for PHR, ranging from a low of $29 to a high of $36, with a standard deviation of $2.34, suggesting a consensus among analysts [2] - The Zacks Consensus Estimate for the current year has increased by 14.4% over the last 30 days, with three estimates moving higher and no negative revisions [11] Group 2 - There is strong agreement among analysts regarding PHR's ability to report better earnings than previously predicted, which supports the expectation of an upside [4][10] - PHR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for near-term upside [12] - While price targets can be misleading, the direction implied by the consensus price target for PHR appears to be a useful guide for potential price movement [9][12]